Literature DB >> 16410387

Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.

Susanne Kern1, Hermann Eichler, Johannes Stoeve, Harald Klüter, Karen Bieback.   

Abstract

Mesenchymal stem cells (MSCs) represent a promising tool for new clinical concepts in supporting cellular therapy. Bone marrow (BM) was the first source reported to contain MSCs. However, for clinical use, BM may be detrimental due to the highly invasive donation procedure and the decline in MSC number and differentiation potential with increasing age. More recently, umbilical cord blood (UCB), attainable by a less invasive method, was introduced as an alternative source for MSCs. Another promising source is adipose tissue (AT). We compared MSCs derived from these sources regarding morphology, the success rate of isolating MSCs, colony frequency, expansion potential, multiple differentiation capacity, and immune phenotype. No significant differences concerning the morphology and immune phenotype of the MSCs derived from these sources were obvious. Differences could be observed concerning the success rate of isolating MSCs, which was 100% for BM and AT, but only 63% for UCB. The colony frequency was lowest in UCB, whereas it was highest in AT. However, UCB-MSCs could be cultured longest and showed the highest proliferation capacity, whereas BM-MSCs possessed the shortest culture period and the lowest proliferation capacity. Most strikingly, UCB-MSCs showed no adipogenic differentiation capacity, in contrast to BM- and AT-MSCs. Both UCB and AT are attractive alternatives to BM in isolating MSC: AT as it contains MSCs at the highest frequency and UCB as it seems to be expandable to higher numbers.

Mesh:

Substances:

Year:  2006        PMID: 16410387     DOI: 10.1634/stemcells.2005-0342

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  980 in total

1.  Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes.

Authors:  Carmen Mariana Aanei; Pascale Flandrin; Florin Zugun Eloae; Eugen Carasevici; Denis Guyotat; Eric Wattel; Lydia Campos
Journal:  Stem Cells Dev       Date:  2011-10-27       Impact factor: 3.272

Review 2.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

3.  Stem cell-derived extracellular matrix enables survival and multilineage differentiation within superporous hydrogels.

Authors:  Melanie Köllmer; Vandana Keskar; Thomas G Hauk; John M Collins; Brenda Russell; Richard A Gemeinhart
Journal:  Biomacromolecules       Date:  2012-03-22       Impact factor: 6.988

4.  Changes of the Functional Capacity of Mesenchymal Stem Cells due to Aging or Age-Associated Disease - Implications for Clinical Applications and Donor Recruitment.

Authors:  Günter Lepperdinger; Regina Brunauer; Robert Gassner; Angelika Jamnig; Frank Kloss; Gerhard Thomas Laschober
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

5.  Fibrin-embedded adipose derived stem cells enhance skin flap survival.

Authors:  Matthias A Reichenberger; Wolf Mueller; Amelia Schäfer; Sina Heimer; Uwe Leimer; Ulrike Lass; Günter Germann; Eva Köllensperger
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

Review 6.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

7.  Conditioned Medium From Azurin-Expressing Human Mesenchymal Stromal Cells Demonstrates Antitumor Activity Against Breast and Lung Cancer Cell Lines.

Authors:  Marília Silva; Gabriel Amaro Monteiro; Arsenio M Fialho; Nuno Bernardes; Cláudia Lobato da Silva
Journal:  Front Cell Dev Biol       Date:  2020-07-09

8.  Cytocompatibility evaluation of different biodegradable magnesium alloys with human mesenchymal stem cells.

Authors:  J Niederlaender; M Walter; S Krajewski; E Schweizer; M Post; Ch Schille; J Geis-Gerstorfer; Hans Peter Wendel
Journal:  J Mater Sci Mater Med       Date:  2013-12-11       Impact factor: 3.896

Review 9.  Activity of mesenchymal stem cells in therapies for chronic skin wound healing.

Authors:  Austin Nuschke
Journal:  Organogenesis       Date:  2013-12-10       Impact factor: 2.500

Review 10.  Tissue engineered bone grafts: biological requirements, tissue culture and clinical relevance.

Authors:  Mirjam Fröhlich; Warren L Grayson; Leo Q Wan; Darja Marolt; Matej Drobnic; Gordana Vunjak-Novakovic
Journal:  Curr Stem Cell Res Ther       Date:  2008-12       Impact factor: 3.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.